ClinicalTrials.gg
RecruitingNCT06250842Updated Apr 11, 2025

Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study

An observational study in Benzodiazepine Adverse Reaction, Depression, Anxiety and Benzodiazepine Dependence, sponsored by The First Affiliated Hospital of Dalian Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by The First Affiliated Hospital of Dalian Medical University · Observational

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.

Read the detailed description

Benzodiazepines(BZDs) have been long-established treatments for various conditions, including anxiety disorders and insomnia. Recent FDA warnings emphasize the risks of misuse and dependence associated with BZDs. Epidemiological investigations have consistently raised concerns regarding the long-term utilization of GABAergic medications, such as BZD and Z-drugs, due to their observed association with an elevated likelihood of neurocognitive impairments, including the development of Alzheimer's disease(AD). Recent neuroimaging studies have provided insights into the neuroprotective effects of BZD. These studies reveal that prolonged use of BZD in humans is associated with reduced amyloid deposition and a greater hippocampus volume. Functional near-infrared spectroscopic imaging utilizes changes in measured near-infrared light to monitor relative changes in oxyhemoglobin and deoxyhemoglobin concentrations in the cerebral cortex, allowing the detection of dynamic changes in cerebral cortical function during cognitive processing states. In this study, investigators will use functional near-infrared spectroscopy (fNIRS) to measure oxygenated (HbO2), deoxygenated hemoglobin (HbR), and total hemoglobin activation in various parts of the cortex, combined with mood and cognitive scales.

Brain metabolism, measured using 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) imaging, can guide clinicians in both research and clinical evaluation, with specific patterns of brain metabolism reduction aiding in the diagnosis of AD or related disorders. The PET tracer DPA-714, binding to the 18 kDa translocator protein (TSPO), provides a non-invasive measure of neuroinflammation in activated microglia/macrophages within the mitochondria. The primary objective of this study is to observe differences in brain functional activation, brain metabolism, and brain neuroinflammatory levels between subjects on long-term BZDs use and those not taking BZDs.

02

Conditions studied

  • Benzodiazepine Adverse Reaction
  • Depression, Anxiety
  • Benzodiazepine Dependence

Keywords

  • Benzodiazepines
  • Long Term Adverse Effects
  • Cognitive Neuroscience
  • Neuroendocrinology
  • immunomodulatory potential
03

In context

Depression

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 100 is below the median of 175 across 1,257 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

The First Affiliated Hospital of Dalian Medical University is the lead sponsor of 42 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The First Affiliated Hospital of Dalian Medical University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Continuous use of benzodiazepines for ≥3 months, matched with participants who have not taken benzodiazepines.
  2. Education time ≥6 years.
  3. Abstained from alcohol, coffee, and other psychoactive substances in the 24 hours before the examination.

Exclusion criteria

Exclusion Criteria:

  1. Brain damage due to various reasons (such as head trauma, dementia, epilepsy, brain tumors, etc.).
  2. Severe systemic diseases (such as malignant tumors, etc.).
  3. Acute cerebrovascular disease in the past 3 months. History of substance abuse other than benzodiazepines (such as alcohol, opioids, etc.).
  4. Inability to cooperate with fNIRS, PET/MRI examinations, and scale assessments.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Long-term benzodiazepine use group

    Continuous use of benzodiazepines for ≥3 months

  • Non-benzodiazepine use group

    No history of prior benzodiazepine use

  • Healthy Controls

    Healthy Controls

06

What researchers measure

Primary outcomes

  1. Brain hemodynamic activity with fNIRS

    This includes changes in the concentration of oxygenated and deoxygenated hemoglobin as measured by the change in light absorption, along with comprehensive analyses of activation values and functional connectivity.

    Time frame: for 3 years

  2. Longitudinal evolution of biomarkers measured from neuroimaging (including structural, functional, and multimodal MRI) and molecular neuroimaging (18F-FDG PET/MRI、DPA-714-PET/MRI)

    Estimates of brain TSPO concentrations measured with PET will serve as a marker for neuroinflammation. Variation of the regional cerebral glucose consumption and TSPO-PET measures, derived from neuroimaging (including structural, functional, and multimodal MRI), will be compared between three groups.

    Time frame: for 3 years

Secondary outcomes

  1. Mini-Mental State Evaluation (MMSE)

    Clinician-administered screening tool used to systematically and thoroughly assess mental status through five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Scores range between 0-30. A score of 25 or higher is classed as normal. If the score is below 24, the result is usually considered to be abnormal, indicating possible cognitive impairment.

    Time frame: About 15 min during the study visit

  2. Scores of Hamilton Depression Scale

    Using to assess depressive symptoms. With higher scores associated with more severe depression symptoms. Total scores \<7 is normal; Mild depression with total scores of 7~17; Moderate depression with total scores of 18~24; Total scores \>24 for severe depression.

    Time frame: About 15 min during the study visit

  3. Scores of Hamilton Anxiety Scale

    Using to assess anxiety symptoms. With higher scores associated with more severe anxiety symptoms. Total scores\< 7 indicates no anxiety; Total scores≥7 indicates possible anxiety; Total scores≥14 indicates anxiety; Total scores≥21 indicates obvious anxiety; Total scores≥29 points indicates serious anxiety.

    Time frame: About 15 min during the study visit

  4. Pittsburgh Sleep Quality Index

    Using to assess the sleep quality. Total scores of 0-5 indicates that the quality of sleep is very good, 6~10 indicates that the quality of sleep is OK, 11~15 indicates that the quality of sleep is average, and 16~21 indicates that the quality of sleep is poor.

    Time frame: About 15 min during the study visit

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06250842
Lead sponsor
The First Affiliated Hospital of Dalian Medical University
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Feb 11, 2024
Primary completion
Feb 20, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 11, 2025

Study contacts

Hui min Zhang
Contact
huiminzhangxs@163.com
+86 18098876233
Mei chen Liu
Contact
meichenliu9019@163.com
+86 18098871637
Hui min Zhang
principal investigator · The First Affiliated Hospital of Dalian Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion